Metabolic syndrome (MS) and inflammation (INF) alterations are hallmarks of cancer progression. The study aimed to firstly assess the relationship between MS and INF and its impact on progression-free/overall survival (PFS/OS) in CRPC pts.
We retrospectively evaluated CRPC pts treated with abi and enza in 7 Italian Institutes between March 2011 and October 2016. MS was defined by modified Adult Treatment Panel III criteria, and INF characterized by the presence of at least 1 of these criteria: NLR≥3, elevated VES or C-reactive protein (CRP) levels.
Eighty-three of 551 pts evaluated (15%) met MS criteria at baseline, whereas for 40 (8.5%) this occurred during treatment. No significant difference of MS incidence and cardiometabolic toxicities were reported between abi or enza. Pts with MS (MS+) showed a greater INF profile compared to MS- (79% vs 28%, p
The presence of MS is strongly associated with INF. Pre-treatment identification of MS and INF alterations may represent an available and easy to perform tool for a better prognostication of CRPC pts treated with abi or enza. A prospective evaluation is warranted.
Clinical trial identification
Legal entity responsible for the study
Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) Srl – IRCCS
V. Conteduca, U. De Giorgi: Speaker honoraria or travel support from Astellas, Janssen-Cilag and Sanofi- Aventis. All other authors have declared no conflicts of interest.